Baybio Panel: The New Norms of HR [7 April 2010]

773 views

Published on

TriNet was invited to host a panel on some of these HR challenges during the conference, and we were excited to facilitate a great discussion between CEOs with growing companies and the 20-25 attendees in the session. We talked about the “New Norms” in HR including growing healthcare and benefits costs, attracting top talent, and the implications of mergers and acquisitions.

See a video excerpt from our panel at http://www.youtube.com/watch?v=dIqB9MacLos

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
773
On SlideShare
0
From Embeds
0
Number of Embeds
12
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Baybio Panel: The New Norms of HR [7 April 2010]

  1. 1. Human Resources Strategies: Defining the New Norms<br />April 7, 2010<br />3:50 – 5:05 PM<br />
  2. 2. Panelists<br />Bruce Cohen President and CEO, VitaPath Genetics<br />Steven R. Deitcher, M.D. President, CEO and Board Member, HanaBiosciences, Inc.<br />Elisa Yu Vice President Operations, CPC Scientific<br />Jack Midgley Vice President Products, TriNet<br />
  3. 3. The “New Normal” ?<br />Escalating Costs of Healthcare Benefits<br />What will healthcare reform really mean for the industry?<br />How shall bio companies respond to escalating costs?<br />Increased Mergers & Acquisitions <br />What does this mean for employees and management?<br />How shall we set expectations and manage outcomes?<br />Challenges Around Hiring & Retention<br />How shall we attract and retain the right scientific, technical and business talent? <br />Increased Outsourcing of “Non-Core” Functions <br />What stays – and what goes?<br />
  4. 4. Escalating Healthcare Costs<br />Employer Responses:<br /><ul><li>Plan Design Changes
  5. 5. Wait Periods
  6. 6. Increasing Employee Share
  7. 7. Adoption of HDHP vs PPO
  8. 8. Differential Funding
  9. 9. After 2014:
  10. 10. Pay the Fine?
  11. 11. Encourage Employees to Buy Through Exchanges?
  12. 12. Changes in Perceived Value of Employer-Sponsored Plans?</li></ul>Average Annual Health Insurance Premiums and Worker Contributions for Family Coverage<br />1999 -2009<br />$13,375<br />132% Employer Cost Increase<br />$5,791<br />Source: http://ehbs.kff.org/pdf/2009/7936.pdf<br />
  13. 13. Increased Mergers and Acquisitions<br /><ul><li>1,171 total deals; $295B committed
  14. 14. 2009 had highest deal volume (193) and 2d highest deal value ($47B) since 2000
  15. 15. 18% of biotech targets had disclosed revenues at time of announcement
  16. 16. Four companies announced multiple acquisitions :
  17. 17. GSK(4)
  18. 18. Amgen (2)
  19. 19. Lilly (2)
  20. 20. Genzyme (2)</li></ul>Biotechnology Mergers and Acquisitions 2000 – 2009<br />Number of Deals by Year<br />2000 - 2009<br />Source: Leading Biotechnology Mergers and Acquisitions for the 10-Year Period Ended December 31, 2009 Revealed by DealSearchOnline.com; 31 March 2010<br />
  21. 21. Smaller, High-Wage Companies Are Hiring More Slowly<br /><ul><li>Are biotech companies accelerating hiring?
  22. 22. What challenges surround scientific, technical and business hiring?</li></ul>US Hiring Index<br />105<br />-2Since January<br />TriNet Hiring Index<br />93<br />-7Since January<br />
  23. 23. Panel Discussion<br />Escalating Costs of Healthcare Benefits<br /><ul><li>What will healthcare reform really mean for the industry?
  24. 24. How shall bio companies respond to escalating costs?</li></ul>Increased Mergers & Acquisitions <br /><ul><li>What does this mean for employees and management?
  25. 25. How shall we set expectations and manage outcomes?</li></ul>Challenges Around Hiring & Retention<br /><ul><li>How shall we attract and retain the right scientific, technical and business talent? </li></ul>Increased Outsourcing of “Non-Core” Functions <br /><ul><li>What stays – and what goes?</li>

×